Clinical aspects of protein glycation
DOI:
https://doi.org/10.15584/ejcem.2017.3.10Keywords:
AGEs, glycation, advanced glycation end products, multiple sclerosisAbstract
Introduction. Glycation is a post-translational modification of proteins that depends on the non-enzymatic linkage of a ketone or aldehyde group of sugar with a free amino group of protein. Pathological effects of this process are observed in many disease states under conditions of hyperglycemia, in diabetic complications, and neurodegenerative diseases such as multiple sclerosis.
Aim. In this paper we present the characteristics of the glycation process, its consequences, as well as a review of current knowledge about the role of glycation in multiple sclerosis.
Material and methods. The databases EBSCO, PubMed, ScienceDirect and SpringerLink were used to search the literature.
Analysis of the literature. Intermediate glycation products form a number of derivatives that contribute to oxidative stress and structural changes in the proteins, including induction of aggregation or reduction of affinity for drug proteins. Glucose products may contribute to neurodegenerative changes in patients with multiple sclerosis. Determination of protein glycation products can be successfully used to evaluate the course of multiple sclerosis as a diagnostic marker.
Downloads
References
Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids. 2003;25:275-281.
Vistoli G, De Maddis D, Cipak A, Zarkovic N, Carini M, Aldini G. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic Res. 2013;47(1):3-27.
Ahmed N. Advanced glycation endproducts ‒ role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67:3-21.
Sajithlal GB, Chithra P, Chandrakasan G. The role of metal-catalyzed oxidation in the formation of advanced glycation end products: an in vitro study on collagen. Free Radic Biol Med. 1998;25:265-269.
Weiss MF, Erhard P, Kader-Attia FA, et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int. 2000;57:2571-2585.
Yamagishi S, Maeda S, Matsui T, Ueda S, Fukami K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta. 2012;1820:663-671.
Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta. 2003;329:23-38.
Seidler NW. Basic biology of GAPDH. Adv Exp Med Biol. 2013;985:1-36.
Rondeau P, Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie. 2011;93:645-658.
Ogawa S, Nakayama K, Nakayama M, et al. Methylglyoxal is a predictor in type 2 diabetic patients of intima-media thickening and elevation of blood pressure. Hypertension. 2010;56:471-476.
Rabbani N, Thornalley PJ. The critical role of methylglyoxal and glyoxalase 1 in diabetic nephropathy. Diabetes. 2014;63:50-52.
Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014;18:1-14.
Negre-Salvayre A, Salvayre R, Augé N, Pamplona R, Portero-Otín M. Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal. 2009;11:3071-3109.
Grillo MA, Colombatto S. Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases. Amino Acids. 2008;35:29-36.
Hashim Z, Zarina S. Advanced glycation end products in diabetic and non-diabetic human subjects suffering from cataract. Age (Dordr). 2011;33:377-384.
Sadowska-Bartosz I, Galiniak S, Bartosz G, Rachel M. Oxidative modification of proteins in pediatric cystic fibrosis with bacterial infections. Oxid Med Cell Longev. 2014;2014:389629.
Sternberg Z, Hennies C, Sternberg D, Wang P, Kinkel P, Hojnacki D, et al. Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosis. J Neuroinflammation. 2010;7:72.
Sadowska-Bartosz I, Adamczyk-Sowa M, Galiniak S, Mucha S, Pierzchala K, Bartosz G. Oxidative modification of serum proteins in multiple sclerosis. Neurochem Int. 2013;63:507-516.
Szkudlarek A, Sułkowska A, Maciążek-Jurczyk M, Chudzik M, Równicka-Zubik J. Effects of non-enzymatic glycation in human serum albumin. Spectroscopic analysis. Spectrochim Acta A Mol Biomol Spectrosc. 2016;152:645-653.
Baraka-Vidot J, Planesse C, Meilhac O, et al. Glycation alters ligand binding, enzymatic, and pharmacological properties of human albumin. Biochemistry. 2015;54:3051-3062.
Nagaraj RH, Linetsky M, Stitt AW. The pathogenic role of Maillard reaction in the aging eye. Amino Acids. 2012;42:1205-1220.
Iberg N, Flückiger R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J Biol Chem. 1986;261:13542-13545.
Hinton DJ, Ames JM. Site specificity of glycation and carboxymethylation of bovine serum albumin by fructose. Amino Acids. 2006;30:425-434.
Zeng J, Davies MJ. Evidence for the formation of adducts and S-(carboxymethyl)cysteine on reaction of alpha-dicarbonyl compounds with thiol groups on amino acids, peptides, and proteins. Chem Res Toxicol. 2005;18:1232-1241.
Pan J, Li Q, Zhang L, et al. Serum glycated albumin predicts the progression of diabetic retinopathy ‒ a five year retrospective longitudinal study. J Diabetes Complications. 2014;28:772-778.
Ma X, Hu X, Zhou J, et al. Glycated albumin is more closely correlated with coronary artery disease than 1,5-anhydroglucitol and glycated hemoglobin A1c. Cardiovasc Diabetol. 2015;14:16.
Hasan NA. Effects of trace elements on albumin and lipoprotein glycation in diabetic retinopathy. Saudi Med J. 2009;30:1263-1271.
Raghav A, Ahmad J. Glycated serum albumin: a potential disease marker and an intermediate index of diabetes control. Diabetes Metab Syndr. 2014;8:245-251.
Koga M. Glycated albumin; clinical usefulness. Clin Chim Acta. 2014;433:96-104.
Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA. 1997;94:6474-6479.
Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110:911-16.e12.
Vlassara H, Uribarri J. Advanced glycation end products (AGE) and diabetes: cause, effect, or both? Curr Diab Rep. 2014;14:453.
Budek Mark A, Poulsen MW, Andersen S, et al. Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care. 2014;37:88-95.
Zhao Z, Zhao C, Zhang XH, et al. Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. Endocrinology. 2009;150:2569-2576.
Ahmad S, Shahab U, Baig MH, et al. Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products. PLoS One. 2013;8:e72128.
Sadowska-Bartosz I, Galiniak S, Bartosz G. Kinetics of glycoxidation of bovine serum albumin by glucose, fructose and ribose and its prevention by food components. Molecules. 2014;19:18828-18849.
Sadowska-Bartosz I, Galiniak S, Skolimowski J, Stefaniuk I, Bartosz G. Nitroxides prevent protein glycoxidation in vitro. Free Radic Res. 2015;49:113-121.
Jariyapamornkoon N, Yibchok-anun S, Adisakwattana S. Inhibition of advanced glycation end products by red grape skin extract and its antioxidant activity. BMC Complement Altern Med. 2013;13:171.
Bogie JF, Stinissen P, Hendriks JJ. Macrophage subsets and microglia in multiple sclerosis. Acta Neuropathol. 2014;128:191-213
Goldenberg MM. Multiple sclerosis review. P.T. 2012;37:175-184.
Ellwardt E, Zipp F. Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. Exp Neurol. 2014;262:8-17.
Runia TF, van Pelt-Gravesteijn ED, Hintzen RQ. Recent gains in clinical multiple sclerosis research. CNS Neurol Disord Drug Targets. 2012;11:497-505.
Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple sclerosis lesions. Brain. 2011;134:1914-1924.
Sternberg Z, Hennies C, Sternberg D, et al. Plasma pentosidine: a potential biomarker in the management of multiple sclerosis. Mult Scler. 2011;17:157-163.
Sternberg Z, Ostrow P, Vaughan M, Chichelli T, Munschauer F. AGE-RAGE in multiple sclerosis brain. Immunol Invest. 2011;40:197-205.
Kalousová M, Havrdová E, Mrázová K, et al. Advanced glycoxidation end products in patients with multiple sclerosis. Prague Med Rep. 2005;106:167-174.
Wetzels S, Wouters K, Schalkwijk CG, Vanmierlo T, Hendriks JJA. Methylglyoxal-derived advanced glycation endproducts in multiple sclerosis. Int J Mol Sci. 2017;18:421.
Guan JZ, Guan WP, Maeda T, Guoqing X, GuangZhi W, Makino N. Patients with multiple sclerosis show increased oxidative stress markers and somatic telomere length shortening. Mol Cell Biochem. 2015;400:183-187.
Fünfschilling U, Supplie LM, Mahad D, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature. 2012;485:517-521.
Choi IY, Lee SP, Denney DR, Lynch SG. Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T. Mult Scler. 2011;17:289-296.
Calabrese V, Scapagnini G, Ravagna A, et al. Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. J Neurosci Res. 2002;70(4):580-587.
Andersson A, Covacu R, Sunnemark D, et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol. 2008;84:1248-1255.
Yan SS, Wu ZY, Zhang HP, et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med. 2003;9:287-293.
Hussain M, Bork K, Gnanapragassam VS, et al. Novel insights in the dysfunction of human blood-brain barrier after glycation. Mech Ageing Dev. 2016;155:48-54.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
